5 reasons AbbVie bought Allergan, and why they may not be enough

AbbVie executives spent an hour Tuesday detailing why buying Allergan was a compelling M&A opportunity. Five reasons stood out as key to the deal. Yet with Tuesday's stock price slide in mind, here's why those may not play out as rosily as expected.